KDM6A loss leads to a better sensitivity to EZH2 inhibitors, denoting that patients with NSCLC with a specific histone methylation pattern may benefit from specific epigenetic modifying therapy [100]. The gene discussed is KDM6A; the disease is non-small cell lung carcinoma.